Source comparison
Hexarelin Oral vs Injectable: Administration Comparison
The table below summarizes the pharmacokinetic, procedural, and application differences between hexarelin oral vs injectable formulations. Bioavailability 60–80% systemic absorption 8–15% systemic absorption Injectable delivers 5–10× higher bioavailability Pea
This comparison does not assign a generated winner or score.
- The table below summarizes the pharmacokinetic, procedural, and application differences between hexarelin oral vs injectable formulations.
- Bioavailability
- 60–80% systemic absorption
- 8–15% systemic absorption
- Injectable delivers 5–10× higher bioavailability
- Peak Plasma Time (Tmax)
- 20–40 minutes
- 60–90 minutes
- Injectable produces faster, sharper GH pulse
- GH Response Amplitude
- 800–1,200% above baseline (rodent models, 100 mcg/kg)
- 150–250% above baseline (500 mcg/kg oral equivalent)
- Injectable required for threshold GH-dependent outcomes
- Dose Equivalency
- 100 mcg subcutaneous
- 500–800 mcg oral (to approximate systemic exposure)
- Oral requires 5–8× higher dose for similar receptor occupancy
- Dosing Frequency
- 1–2× daily (mimics pulsatile GH secretion)
- 3× daily (to maintain threshold plasma levels)
- Injectable better suited to physiological pulsatility
- Preparation Requirements
- Reconstitution, refrigeration (2–8°C), aseptic technique
- No preparation; room-temp stable if lyophilized
- Oral simpler operationally; injectable requires lab infrastructure
- First-Pass Metabolism
- None (bypasses GI tract and liver)
- Extensive (gastric acid + hepatic enzymes degrade 85–92%)
- Injectable preserves peptide structural integrity
- Research Applications
- GH/IGF-1 studies, anabolic/neuroprotective endpoints
- GHS-R1a behavior studies, orexigenic signaling, chronic low-dose modulation
- Route selection must align with primary endpoint
- Participant Compliance (Human Studies)
- Requires trained administration; procedural burden
- Self-dosing; higher compliance in outpatient settings
- Oral preferred for long-duration observational studies
- Inter-Subject Variability
- Low (dose-proportional response)
- High (gastric pH, fed/fasted state, hepatic enzyme polymorphism)
- Injectable produces more consistent plasma exposure